Objective:To construct the extracellular region of the human TRAIL cDNA expression vector and express and purify the extracellular region of the TRAIL protein. Methods: The mRNA of TRAIL was extracted from CD3 activated normal human PBMC and used as a template for reverse transcription. After PCR amplification, a 730 bp fragment including extracellular region was obtained and cloned into pGEX-2T.The recombinant vector was named pGEX/TRAILex. The pGEX/TRAILex vector was transformed into E.coli DH5a. After IPTIG induced at lower temperature, the collection of the sonicated extract was purified by using the GST agarose 4B. The purified fusion protein was identified by Western blotting with anti-TRAIL McAb.Results:The pGEX/TRAILex was constructed. After IPTG induced,a high level expression of the extracellular region of the TRAIL protein was obtained, SDS-PAGE analysis showed that the recombinant E. coli could express a 54 kD GST fusion protein which accounted for about 28% of the total cellular protein. The study of solubility of expression protein indicated that GST-Tex was expressed predominantly in the soluble form.The purified production was obtained 2.2 mg/L of culture media and the purity of the GST-Tex was more than 95%. GST/TRATLex protein could be recognized by anti-TRAL McAb in Western blot. Conclusion:The expression of recombinant extracellular domain of the human TRAIL protein may be useful for the study of biological functions of TRAIL and it's biotheraphy in tumor.

Objective To identify genomic DNA of Schistosoma ?. Methods Amplification of genomic DNA by the random-amplified polymorphic DNA polymerase chain reaction (RAPD-PCR) with 10-base pair was used. The 50 worms were collected from rabbits infected with cercariae of S.? and Schistosoma japonicum(S.j.) respectively. RAPD-PCR were performed on PCR-2400 according to the manufature's instruction. And 29 primers were adopted from Operon Company. The samples were run on 1.4% sepharose. Results RAPD fragments produced were various in quantity(4-12 bands)and size(0.5-5.2Kb) in S.? and S.j. , most of about 224 bands produced with 27 different primers were common, but 6 differential bands produced with 2 primers (J 01 CCCGGCATAA and L 12 GGGCGGTACT) of the 29 primers were found, 4 and 2 of the 6 differential bands seen in the S.? and S.j. respectively. Conclusion These specific fragments found in S.? and S.j. may be used as molecular markers for the identification of S.? and S.j.

Objective To explore the gray matter changes in aggressive patients with schizophrenia,and the relationship between the gray matter and aggression in patients.Methods Eighteen aggressive patients with schizophrenia (SZ1),18 age-and gender-matched un-aggressive patients with schizophrenia (SZ2) and 18 normal controls (NC) were enrolled in the study.Then a 3.0 T magnetic resonance imaging (MRI) scan was conducted for each participant.The voxel-based morphometry (VBM) approach and the Chinese version of Buss & Perry aggression questionnaire (B&P) were used to explore imaging data and to assess the aggression,respectively.Results Compared with NC,patients with schizophrenia showed changes in gray matter volume (GMV) in the frontal,temporal and the occipital lobes (P＜0.05,AlphaSim corrected).Compared with SZ2,SZ1 showed increased GMV in the right supramarginal gyrus,right postcentral gyms,bilateral insula and orbito-frontal gyri (P＜0.05,AlphaSim corrected).The GMV of the right insula,right postcentral gyms and right supramarginal grus were positively associated with B&P scores in patients with schizophrenia (P＜0.01,AlphaSim corrected),respectively.Conclusions These preliminary findings support that the aggression in schizophrenia is associated with GMV changes of brain regions in patients with schizophrenia.The right postcentral gyrus,the right insula and the right supramarginal gyrus may be involved in the neural mechanism of aggression in schizophrenia.

24 new cDNA sequences encoding cytochrome P450 were amplified respectively from deltamethrin susceptible and -resistant strains of the mosquito, Culex pipiens pallens, with a pair of degenerate primers according to the conservative amino acid sequences of CYP4 in insects by RT-PCR. Studies of molecular systematics show that the 24 new genes (alleles) belong to CYP4C, CYP4D, CYP4H and CYP4J subfamilies of the CYP4 family, and they were named by Cytochrome P450 Nomenclature Committee. Among the new genes (alleles), CYP4C23 may be a pseudogene, CYP4H13 has a retained intron 58 nucleotides in length, and CYP4J4V1 has a stop coden (TAG) in frame near the 3'-end.

Objective To learn the latest progress in the research of ω-3 unsaturated fatty acids and provide references for the related investigator through visualized analysis of the research of ω-3 unsaturated fatty acids published in our country.Methods China Biology Medicine disc was searched by computer from the beginning until December 31,2017.Bibliographic Item Co-occurrence Mining System (BICOMS) was used to extract and summarize the data of age,author,organization,province and key words and to produce a co-occurrence matrix.NetDraw of Ucinet 6.0 was employed to draw the social network diagram of the author,organization,province and key words.And cluster analysis of the key words was performed by gCLUTO 2.0.Results A total of 1 165 studies involviug 30 provinces and cities,854 research units,3 789 authors and 1 016 significative key words were included.The cooperation of author,organization and province needed to be further strengthened.The study focused on 3 aspects:the effects of unsaturated fatty acids on apoptosis/lipid in mice/rats with related genes of diabetes/cardiovascular disease/coronary artery disease;meta-analysis of immunonutrition to improve tumor/inflammation/sepsis;effect of fish oil fat emulsion on interleukin/C reactive protein in pneumonia/lung injury.Conclusions The research of ω-3 unsaturated fatty acids develops rapidly in China,but it is mainly concentrated in a few centers of cooperation agencies.There is little cooperation among different provinces,cities,areas,and organizations and the research topics needs to be further expanded.

Background/Aims: Roxadustat, an oral medication for treating renal anemia, is a hypoxia-inducible factor prolyl hydroxylase inhibitor used for regulating iron metabolism and promoting erythropoiesis. To investigate the efficacy and safety of roxadustat in patients undergoing peritoneal dialysis (PD) with erythropoietin hyporesponsiveness. Methods: Single-center, retrospective study, 81 PD patients (with erythropoietin hyporesponsiveness) were divided into the roxadustat group (n = 61) and erythropoiesis-stimulating agents (ESAs) group (n = 20). Hemoglobin (Hb), total cholesterol, intact parathyroid hormone (iPTH), brain natriuretic peptide (BNP), related indicators of cardiac function and high-sensitivity C-reactive protein (hs-CRP) were collected. Additionally, adverse events were also recorded. The follow-up period was 16 weeks. Results: The two groups exhibited similar baseline demographic and clinical characteristics. At baseline, the roxadustat group had a mean Hb level of 89.8 ± 18.9 g/L, while the ESAs group had a mean Hb level of 95.2 ± 16.0 g/L. By week 16, the Hb levels had increased to 118 ± 19.8 g/L (p < 0.05) in the roxadustat group and 101 ± 19.3 g/L (p > 0.05) in the ESAs group. The efficacy of roxadustat in improving anemia was not influenced by baseline levels of hs-CRP and iPTH. Cholesterol was decreased in the roxadustat group without statin use. An increase in left ventricular ejection fraction and stabilization of BNP were observed in the roxadustat group. Conclusions For PD patients with erythropoietin hyporesponsiveness, roxadustat can significantly improve renal anemia. The efficacy of roxadustat in improving renal anemia was not affected by baseline levels of hs-CRP0 and iPTH.